Mesoblast (MESO) Income from Continuing Operations (2015 - 2023)
Mesoblast recorded quarterly Income from Continuing Operations of 21575000.0 in Q2 2023, down 15.42% quarter-over-quarter from 18692000.0 in Q1 2023, and down 2.34% year-over-year from 22092707.78 in Q2 2022.
Mesoblast's Income from Continuing Operations history runs 9 years deep, the most recent figure standing at 21575000.0 for Q2 2023.
- In Q2 2023, Income from Continuing Operations fell 2.34% year-over-year to 21575000.0; the TTM figure through Jun 2023 stood at 81889000.0 (up 10.35% YoY), while the FY2025 annual figure was 102142000.0, down 16.13% from the prior year.
- Income from Continuing Operations came in at 21575000.0 for Q2 2023 at Mesoblast, down from 18692000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 9348000.0 in Q3 2019 to a low of 29380000.0 in Q1 2019.
- A 5-year average of 22580222.22 and a median of 22172000.0 in 2021 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations soared 55.32% in 2019 and tumbled 178.18% in 2020, its largest moves.
- Mesoblast's Income from Continuing Operations stood at 29122000.0 in 2019, then rose by 12.29% to 25544000.0 in 2020, then fell by 2.2% to 26105000.0 in 2021, then climbed by 5.66% to 24628000.0 in 2022, then rose by 12.4% to 21575000.0 in 2023.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 21575000.0, 18692000.0, and 24628000.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Mesoblast | 23.40 Bn | 23.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -21.58 Mn |
| Mar 31, 2023 | -18.69 Mn |
| Dec 31, 2022 | -24.63 Mn |
| Sep 30, 2022 | -16.99 Mn |
| Jun 30, 2022 | -21.08 Mn |
| Mar 31, 2022 | -21.39 Mn |
| Dec 31, 2021 | -26.11 Mn |
| Sep 30, 2021 | -22.77 Mn |
| Jun 30, 2021 | -20.55 Mn |
| Mar 31, 2021 | -26.71 Mn |
| Dec 31, 2020 | -25.54 Mn |
| Sep 30, 2020 | -26.00 Mn |
| Jun 30, 2020 | -20.29 Mn |
| Mar 31, 2020 | -19.17 Mn |
| Dec 31, 2019 | -29.12 Mn |
| Sep 30, 2019 | -9.35 Mn |
| Jun 30, 2019 | -27.08 Mn |
| Mar 31, 2019 | -29.38 Mn |
| Dec 31, 2018 | -30.33 Mn |
| Sep 30, 2018 | -20.92 Mn |
| Jun 30, 2018 | -22.88 Mn |
| Mar 31, 2018 | -27.99 Mn |
| Dec 31, 2017 | -32.98 Mn |
| Sep 30, 2017 | -12.82 Mn |
| Jun 30, 2017 | -35.33 Mn |
| Mar 31, 2017 | -15.97 Mn |
| Dec 31, 2016 | -26.30 Mn |
| Sep 30, 2016 | -26.01 Mn |
| Jun 30, 2016 | -116.72 Mn |
| Mar 31, 2016 | -21.12 Mn |
| Dec 31, 2015 | -22.33 Mn |